In conclusion, based on vast evidence from literature and clinical trials, we believe that therapies combining clinically-administered therapeutic regimens with CAIX targeting could improve the efficacy of anti-tumor response in patients with pancreatic ductal adenocarcinoma. The gene discussed is CA9; the disease is neoplasm.